1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-infective Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anti-infective Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
5.2. Regulatory Scenario, by Region
5.3. Reimbursement Scenario by Region/Globally
5.4. Pipeline Analysis
5.5. Key Product/Brand Analysis
5.6. Key Mergers & Acquisitions
5.7. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Anti-infective Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Antibacterials
6.3.1.1. B-lactams
6.3.1.2. Quinolones
6.3.1.3. Macrolides
6.3.1.4. Tetracycline
6.3.1.5. Aminoglycoside
6.3.1.6. Others
6.3.2. Antivirals
6.3.2.1. Miscellaneous Antivirals
6.3.2.2. Adamantane Antivirals
6.3.2.3. Antiviral Boosters
6.3.2.4. Others
6.3.3. Antifungals
6.3.3.1. Azoles
6.3.3.2. Echinocandins
6.3.3.3. Polyenes
6.3.3.4. Others
6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Anti-infective Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Others
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Anti-infective Drugs Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017-2031
8.3.1. Pneumonia
8.3.2. Sepsis
8.3.3. Tuberculosis
8.3.4. Influenza
8.3.5. HIV Infection
8.3.6. Hepatitis Virus Infection
8.3.7. Respiratory Virus Infection
8.3.8. Others
8.4. Market Attractiveness Analysis, by Indication
9. Global Anti-infective Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Anti-infective Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Anti-infective Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Antibacterials
11.2.1.1. B-lactams
11.2.1.2. Quinolones
11.2.1.3. Macrolides
11.2.1.4. Tetracycline
11.2.1.5. Aminoglycoside
11.2.1.6. Others
11.2.2. Antivirals
11.2.2.1. Miscellaneous Antivirals
11.2.2.2. Adamantane Antivirals
11.2.2.3. Antiviral Boosters
11.2.2.4. Others
11.2.3. Antifungals
11.2.3.1. Azoles
11.2.3.2. Echinocandins
11.2.3.3. Polyenes
11.2.3.4. Others
11.2.4. Others
11.3. Market Value Forecast, by Route of Administration, 2017-2031
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Others
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Pneumonia
11.4.2. Sepsis
11.4.3. Tuberculosis
11.4.4. Influenza
11.4.5. HIV Infection
11.4.6. Hepatitis Virus Infection
11.4.7. Respiratory Virus Infection
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Route of Administration
11.7.3. By Indication
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe Anti-infective Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Antibacterials
12.2.1.1. B-lactams
12.2.1.2. Quinolones
12.2.1.3. Macrolides
12.2.1.4. Tetracycline
12.2.1.5. Aminoglycoside
12.2.1.6. Others
12.2.2. Antivirals
12.2.2.1. Miscellaneous Antivirals
12.2.2.2. Adamantane Antivirals
12.2.2.3. Antiviral Boosters
12.2.2.4. Others
12.2.3. Antifungals
12.2.3.1. Azoles
12.2.3.2. Echinocandins
12.2.3.3. Polyenes
12.2.3.4. Others
12.2.4. Others
12.3. Market Value Forecast, by Route of Administration, 2017-2031
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Others
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Pneumonia
12.4.2. Sepsis
12.4.3. Tuberculosis
12.4.4. Influenza
12.4.5. HIV Infection
12.4.6. Hepatitis Virus Infection
12.4.7. Respiratory Virus Infection
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Route of Administration
12.7.3. By Indication
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Anti-infective Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Antibacterials
13.2.1.1. B-lactams
13.2.1.2. Quinolones
13.2.1.3. Macrolides
13.2.1.4. Tetracycline
13.2.1.5. Aminoglycoside
13.2.1.6. Others
13.2.2. Antivirals
13.2.2.1. Miscellaneous Antivirals
13.2.2.2. Adamantane Antivirals
13.2.2.3. Antiviral Boosters
13.2.2.4. Others
13.2.3. Antifungals
13.2.3.1. Azoles
13.2.3.2. Echinocandins
13.2.3.3. Polyenes
13.2.3.4. Others
13.2.4. Others
13.3. Market Value Forecast, by Route of Administration, 2017-2031
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Others
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Pneumonia
13.4.2. Sepsis
13.4.3. Tuberculosis
13.4.4. Influenza
13.4.5. HIV Infection
13.4.6. Hepatitis Virus Infection
13.4.7. Respiratory Virus Infection
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Route of Administration
13.7.3. By Indication
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Anti-infective Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Antibacterials
14.2.1.1. B-lactams
14.2.1.2. Quinolones
14.2.1.3. Macrolides
14.2.1.4. Tetracycline
14.2.1.5. Aminoglycoside
14.2.1.6. Others
14.2.2. Antivirals
14.2.2.1. Miscellaneous Antivirals
14.2.2.2. Adamantane Antivirals
14.2.2.3. Antiviral Boosters
14.2.2.4. Others
14.2.3. Antifungals
14.2.3.1. Azoles
14.2.3.2. Echinocandins
14.2.3.3. Polyenes
14.2.3.4. Others
14.2.4. Others
14.3. Market Value Forecast, by Route of Administration, 2017-2031
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Others
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Pneumonia
14.4.2. Sepsis
14.4.3. Tuberculosis
14.4.4. Influenza
14.4.5. HIV Infection
14.4.6. Hepatitis Virus Infection
14.4.7. Respiratory Virus Infection
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Route of Administration
14.7.3. By Indication
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Anti-infective Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017-2031
15.2.1. Antibacterials
15.2.1.1. B-lactams
15.2.1.2. Quinolones
15.2.1.3. Macrolides
15.2.1.4. Tetracycline
15.2.1.5. Aminoglycoside
15.2.1.6. Others
15.2.2. Antivirals
15.2.2.1. Miscellaneous Antivirals
15.2.2.2. Adamantane Antivirals
15.2.2.3. Antiviral Boosters
15.2.2.4. Others
15.2.3. Antifungals
15.2.3.1. Azoles
15.2.3.2. Echinocandins
15.2.3.3. Polyenes
15.2.3.4. Others
15.2.4. Others
15.3. Market Value Forecast, by Route of Administration, 2017-2031
15.3.1. Oral
15.3.2. Parenteral
15.3.3. Others
15.4. Market Value Forecast, by Indication, 2017-2031
15.4.1. Pneumonia
15.4.2. Sepsis
15.4.3. Tuberculosis
15.4.4. Influenza
15.4.5. HIV Infection
15.4.6. Hepatitis Virus Infection
15.4.7. Respiratory Virus Infection
15.4.8. Others
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Route of Administration
15.7.3. By Indication
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by Tier and Size of Companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Pfizer Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Gland Pharma Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Teva Pharmaceutical Industries Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. F. Hoffmann-La Roche Ltd.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Gilead Sciences, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Merck & Co., Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Abbott
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Astellas Pharma Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Alkem Laboratories
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. AstraZeneca
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Eli Lilly and Company
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Johnson & Johnson Services, Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Takeda Pharmaceutical Company Limited
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. Sanofi
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Product Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview
Table 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 03: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 04: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 05: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 06: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 08: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 09: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 10: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 11: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 12: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 13: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 14: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 16: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 17: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 18: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 19: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 20: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 21: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 22: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 23: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 26: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 27: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 28: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 29: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 30: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 31: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 32: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 33: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 34: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 35: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 36: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 37: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 38: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 39: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 40: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 41: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 42: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
Table 43: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
Table 44: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
Table 45: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 46: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 47: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 48: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
